1. Introduction {#sec1}
===============

Myeloid sarcoma (MS) is an extra-medullary solid tumor caused by an abnormal proliferation of primitive immature precursors of the granulocytic series of white blood cells.[@bib1] First described in 1811, MS is also called "chloroma" because of its green color secondary to the presence of intracellular myeloperoxidase.[@bib2]^,^[@bib3] Subsequently, because of its macroscopic appearance variability, the tumor was renamed granulocytic sarcoma in 1966.[@bib4]

MS is a rare disease, often related to other underlying unrecognized myeloproliferative conditions. Indeed, MS occurs in 2.5--9.1% of patients with acute myeloid leukemia (AML).[@bib27] Less frequently it occurs as a harbinger of AML in non-leukemic patients, or in association with myelodysplastic disorders or chronic myeloid leukemia (CML) with impending blast crisis.[@bib1]^,^[@bib2] In pediatric population, orbit is one of the most common sites of occurrence.[@bib1]

The correct diagnostic assessment of orbital MS is challenging due to its uncommon presentation and to the high number of possible mimickers, by both clinical and radiological examination. Nevertheless, a prompt diagnosis is important especially in patients with a non-leukemic presentation, because AML-type chemotherapy and or allogeneic hematopoitic cell transplantation improves overall free survival.[@bib5]

Herein we report two rare cases of orbital MS in a 2 young male patients without evidence of AML, detailing their magnetic resonance imaging (MRI) features and highlighting possible pitfalls and useful clues in neuroradiological differential diagnosis. A comprehensive literature review of all included reports were available from PubMed, PMC and MEDLINE database of references and abstracts.

Only pediatric-onset MS were included in the literature revision. Orbit involvement was considered positive when solid tissue was documented at CT/MRI examination within the orbital pyramid, independently of possible site of origin; association with AML or other myeloproliferative diseases (MDs) was considered positive both when myeloproliferative neoplasm preceded, co-occurred with or followed the diagnosis of MS. Publications in other languages than English and previous literature reviews have not been considered in this analysis.

2. Case 1 {#sec2}
=========

A caucasian 14-year-old boy came to the Orbital Pathology Department with one-month history of left eye upper and lower eyelid swelling, refractory to corticosteroid therapy. His previous ocular, personal and family history was negative. At physical examination eyelid edema, conjunctive hyperemia and inferior displacement of the left eye were detected, with exotropic deviation of about 2mm at Hirschberg test. Upright clinical exophthalmometry revealed a severe protrusion (33mm) of the left eyeball. At infrared oculography voluntary eye movements were unilaterally restricted in all directions, excepted for adduction that was preserved. Visual acuity on Early Treatment Diabetic Retinopathy Study chart rows and fundus examination were normal.

Ultrasonography revealed a well-circumscribed mass characterized by heterogeneous mild echogenicity, with moderate intra-lesional vascularity at doppler US, located in the upper and lateral quadrant of the orbit. MRI examination confirmed the presence of a supero-lateral extra-conal orbital mass (maximum diameters 38 × 20 × 37mm, approximate volume 10 cm^3^) between the superior and lateral rectus muscles occupying in the lacrimal fossa ([Fig. 1](#fig1){ref-type="fig"}a and b). The lesion was isointense on T2w and slightly hyperintense on T2w images compared to muscle tissue, with restricted water diffusion on diffusion weighted imaging (DWI) indicating hypercellularity ([Fig. 1](#fig1){ref-type="fig"}c and d). Lacrimal gland was not clearly dissociable from the mass, and focal bony erosion and invasion of the lateral wall of the orbit were also noted ([Fig. 2](#fig2){ref-type="fig"}a, *white arrow*). After gadolinium injection the lesion presented with in homogeneous and vivid contrast enhancement with a small inner necrotic core ([Fig. 2](#fig2){ref-type="fig"}b--d, *black arrow*). Dynamic contrast-enhanced (DCE) MRI perfusion demonstrated fast contrast media wash-in and wash-out, highly suggestive for malignancy. The mass caused displacement without infiltration of adjacent muscles, as well as minimal dislocation of the optic nerve. A locally infiltrating solid tumor, possibly sarcomatous, was then hypothesized. The patient underwent left lateral orbitotomy for biopsy, and possibly lesion maximal resection. A whitish fish-flesh tumor with some internal hemorrhage compressing the adjacent structures was found, and a gross total tumor resection was carried out.Fig. 1Axial (a) and coronal (b--d) T2w images showing expansive extra-conal orbital lesion arising along the external border of superior and lateral rectus muscles and superior oblique muscle. The lesion presents mild hyperintensity with inhomogeneous core, and slightly restricted water diffusion on DWI (c) indicating hypercellularity. Extra-ocular muscles and optic nerve are displaced (*white dotted line*); marked left eye proptosis is also present. The lesion does not spear lacrimal gland that seems to be infiltrated (*not shown*); bony erosion and invasion of the lateral wall of the orbit are clearly visible (*white arrow*).Fig. 1Fig. 2Axial pre (a) and post-contrast (b) T1w showing lesion vivid enhancement and inner un-enhancing necrotic area (*black arrow*); the great wing of the sphenoid seems to be infiltrated (*white arrow*). Multi-planar reconstruction on coronal plane shows lesion extent from the lacrimal fossa of the frontal bone (c) (*black arrowhead*) to the orbital apex (d) (*white arrowhead*).Fig. 2

Pathological examination revealed a cohesive proliferation of small to medium-sized cells with large oval and often indented nuclei, prominent nucleoli and scant cytoplasm (myeloblast-like), mixed with a discrete number of eosinophils ([Fig. 3](#fig3){ref-type="fig"}a--d). Neoplastic cells expressed leucocyte common antigen (LCA/CD45RO), CD68 and myeloperoxidase (MPO); there was also a focal reactivity for CD34. Ki-67 staining was 50% ([Fig. 3](#fig3){ref-type="fig"}e--h). Final diagnosis was consistent with MS. Due to the common association with AML, blood sampling was collected to document the presence of altered white blood cell count; final results did not showed peripheral blood abnormalities. Bone marrow aspirate was negative for tumor infiltration.Fig. 3Low and high magnification lesion histology after surgery: (a) low magnification showing a dense, diffuse infiltrate (H&E 4×); (b) the tumor consists of a cohesive proliferation of small/medium-sized cells (H&E 10×); (c) a discrete number of eosinophils are admixed with tumor cells (H&E 20×); (d) neoplastic cells show large oval nuclei, prominent nucleoli and poor cytoplasm (H&E 40×). Lesion immunophenotype: (e--g) neoplastic cells diffusely expressed CD45RO/LCA (anti-CD45RO/LCA, 40×), CD68 (anti-CD68, 40×) and myeloperoxidase (anti-MPO, 40×); (h) Ki-67 proliferative index is positive in about 50% of neoplastic cells (anti-Ki-67, 40×).Legend: H&E = hematoxylin and eosin stain.Fig. 3

After surgery followed by 1 month of induction chemotherapy according to European Leukemia Network recommendations for AML treatment, proptosis resolved and MRI demonstrated no evidence of residual and/or recurrent local disease. The patient is under clinical, laboratory and radiological follow-up with no sign of recurrence after one year from surgery.

3. Case 2 {#sec3}
=========

4 year old boy presented to Emergency room at King Khaled Eye Specialist Hospital with a growing mass in right upper lid over the last one month. He is medically free and his previous ocular, personal and family history was negative. On examination visual acuity in the right eye was 20/50 and left eye was 20/30. Extraocular muscle movement was full in both eyes. Pupil round, regular and reactive with no relative afferent pupillary defect on both sides. Examination grossly of the right eye showed well circumscribed upper and medial mass about 3 × 2 cm in size with smooth surface. It was hard in consistency but non-tender or mobile. The globe was displaced inferiorly with exotropia. The overlying skin was normal with no discoloration. Slit lamp examination showed normal anterior segment and fundus examination was unremarkable in both eyes.

MRI examination confirmed the presence of an extraocular solid mass involving the superior aspect of the right orbit with intermediate signal intensity on T1-weighted and T2-weighted image which was seen infiltrating and extending through the pre-septal into the post-septal part. It was a well-defined mass and measured approximately 3.5 × 2.4 cm in diameter with subsequent minimal displacement of the related part of the right globe. The mass lesion had marked restricted pattern on diffusion weighted image(ADC value equal to 0.475 × 10^(−3)^ mm^(2)^/sec) ([Fig. 4](#fig4){ref-type="fig"}a--d). The mass was seen separated from the medial rectus muscle and abutting the superior rectus muscle and displacing the superior oblique with evidence of mild degree of prominent vascularities. There was no evidence of bony infiltration and no evidence of intraspinous nor intracranial extension. Rhabdomyosarcoma was clinically suspected. The patient underwent incisional biopsy which showed a yellow-grey mass.Fig. 4Axial CT scan orbit (a) and sagittal T1 fat suppressed post contrast (b,c) and axial DWI (D) images showing solid lobulated extra-conal orbital lesion arising superiorly along the orbital roof and nasal infiltrating the recti muscles and superior oblique muscle. The lesion presents marked restricted water diffusion on DWI (c) indicating high degree of cellularity. The lesion abutting the lacrimal gland with no definite line of separation.Fig. 4

Pathological examination revealed a highly vascular soft tissue of poorly differentiated malignant cells infiltrating the adipose tissue with few eosinophils suggestive of malignant orbital tumor in the right eye, The tumor cells expressed the following immunohistochemical markers: CD45, 34, 43, 117, Lysozyme, CD68 (KP1) and Myeloperoxidase indicating myeloid lineage but did not show expression of CD20 and CD3 ([Fig. 5](#fig5){ref-type="fig"}a--d).Fig. 5Low and high magnification lesion histology after surgery: (a) high magnification showing a highly vascular soft tissue of poorly differentiated malignant cells infiltrating the adipose tissue with eosinophils (H&E 400×); (b) low magnification showing a dense, diffuse infiltrate (H&E 100×); (c) CD34 expression in neoplastic cells (CD34, ×100) (d) neoplastic cells diffusely expressed CD45RO/LCA (anti-CD45RO/LCA, 100×).Legend: H&E = hematoxylin and eosin stain.Fig. 5

Final diagnosis was consistent with MS and because of common association with AML, blood sampling was collected to document the presence of altered white blood cell count; final results was unremarkable except for below normal neutrophils. The patient referred to King Faisal Specialist Hospital and Research center and started systemic chemotherapy with a complete remission at 6 months follow up. At present, the patient is under clinical, laboratory and radiological follow-up with no sign of recurrence at four years from surgery.

4. Discussion {#sec4}
=============

MS is a rare condition occurring in 2.5--9.1% patients with AML; it is characterized by the presence of one or more tumor masses in extra-medullary sites such as bone, subcutaneous tissues, orbit, lymph nodes, gastro-intestinal tract and central nervous system[@bib6] In pediatric population skin and orbit constituted the most common sites of invasion.[@bib7] Scattered isolated cases of pediatric orbital MS have been described, frequently associated to a high misdiagnosis rate. Isolated orbital MS frequently exhibits clinical features mimicking inflammatory process or lymphoproliferative disease.[@bib8], [@bib9], [@bib10], [@bib11], [@bib12], [@bib13] The most frequent manifestation is the unilateral exophthalmos; other possible signs include ptosis, painful lacrimal gland swelling, conjunctival mass, retinal hemorrhages, diffuse iris or uveal alterations.[@bib7] We are presenting two cases with isolated orbital MS that were associated with dystopia.

In patients whose anamnesis is positive for hematologic malignancies, the diagnosis of MS is relatively easy to evoke, while diagnosis of primary MS with no AML can be challenging[@bib14] and imaging assessment become then crucial. In these cases, differential diagnosis with orbital infections and inflammations can be performed with the use of diffusion weighted and contrast-enhanced imaging techniques.[@bib16], [@bib17], [@bib18], [@bib19], [@bib20] Other more challenging mimickers to be considered include vascular lesion, lymphoma (especially African Burkitt), metastatic neuroblastoma and rhabdomyosarcoma. Dynamic contrast-enhanced Computed Tomography (CT) or MRI can be very helpful in demonstrating the vascular nature of these lesions because of their progressive enhancement, starting from a small and generally central portion and then filling up the entire mass; eventually this enhancement pattern is typically associated to benign findings.[@bib15] Orbital lymphoid tumors are rare in children, with the only exception of Burkitt lymphoma; in this setting, lymphoid tissue commonly shows lower apparent diffusion coefficient values compared to other neoplastic lesions.[@bib15] Neuroblastoma metastases are not rare in pediatric population, but they are generally associated with important focal bony destruction and invasion of adjacent structures.[@bib16] Rhabdomyosarcoma imaging features might be not clearly distinguishable from MS. Few clues may help the radiologist in correct assessment, such as a marked involvement of muscles that is not frequently observed in MS.[@bib24]

It has been reported that orbital MS on CT appears as a well-defined mass, isodense or hyperdense to brain tissue, with homogeneous enhancement after contrast media injection. However, in some cases it can exhibit heterogeneous enhancing with non-enhancing areas corresponding to the inner necrotic areas, which is considered by some as a sign of rapid growth.[@bib25] On MRI images, the orbital lesion appears isointense or slightly hypointense to the brain both on T1w and T2w images. With gadolinium contrast enhancement, it can present with a more or less homogeneous enhancement depending on the presence of necrotic areas within the mass. Associated bone marrow involvement and low signal intensity on T2w imaging may be helpful in differentiating these tumors from other lesions.[@bib20], [@bib22] MRI has been proved to provide useful and more comprehensive information for lesion characterization compared to CT scan, avoiding any exposure to ionizing radiation.[@bib19], [@bib20], [@bib21] In the first case the MRI showed mild hyperintensity on T2w images, with inhomogeneous core and slightly restricted water diffusion due to hypercellularity; vivid enhancement and inner un-enhancing necrotic area after contrast administration along with adjacent bone infiltration helped in differential diagnosis of malignancy ([Fig. 1](#fig1){ref-type="fig"}, [Fig. 2](#fig2){ref-type="fig"}). While in the second case the solid mass lesion showed intermediate signal intensity on T1-weighted and T2-weighted image which was seen infiltrating and extending through the pre-septal into the post-septal part. Diffusion weighted image (DWI) demonstrating high signal at the site of the mass indicating restricted diffusion, likely reflecting increased cellularity ([Fig. 4](#fig4){ref-type="fig"}). Differential considerations include lymphoma, rhabdomyosarcoma or other malignant mass with high dense cellularity.[@bib32]

However, despite the guidance given by an accurate neuroradiological examination, biopsy remains the only method for a final diagnostic assessment particularly in patients who develop granulocytic sarcoma in absence of a diagnosis of leukemia. In this study, immunohistochemical staining for myeloid markers, such as CD45RO/LCA (anti-CD45RO/LCA) CD68 (anti-CD68, and myeloperoxidase (anti-MPO) allowed the diagnosis. Cell surface markers including CD4, CD30, CD34, TdT, and glycophorin A are also useful for diagnosis of MS.[@bib23] Among the various markers, MPO, lysozyme, and CD68 are the most sensitive and essential markers for myeloid differentiation in addition to molecular genetic.[@bib24]^,^[@bib33]

Alkatan and Chaudhry,[@bib31] documented that FISH using the DNA probe for t(8; 21) was positive in only 2% of the cells, which was significant for the diagnosis and expected prognosis since the finding of such translocation is expected to be associated with higher chance for the development of systemic leukemia.

When comparing our observation to current literature reports, out of the 243 cases reported from 1978 to present time ([Table 1](#tbl1){ref-type="table"}), around 10% patients (*n* = 25) presented with an isolated lesion with no evidence of AML. Indeed, the majority (*n* = 218) were preceded, accompanied or followed by the evidence of generalized hematopoietic malignancies. Interestingly, two isolated cases had history of orbital trauma preceding the onset,[@bib15] proposed to be a possible trigger event for the onset of this type of malignancy; however, further evidences need to be collected to verify this hypothesis. A more detailed description of literature review in term of location of orbital mass, key finding, laterality, risk factor, association with acute myelocytic leukemia and myelodysplastic disease, type of treatment and prognosis on pediatric myeloid sarcoma is provided in ([Table 2](#tbl2){ref-type="table"}).Table 1Summary of main findings described in current scientific literature on pediatric myeloid sarcoma (MS) with orbital involvement.Table 1n%Total Orbital MS Reports243100No MDs2510.3MDs21889.7AML21588.4CML10.41Other20.82Risk factorsAbsent21688.8Trauma20.82Surgery00Other00[^1]Table 2Articles included in the literature review on Pediatric myeloid sarcoma (MS) with orbital involvement until 2019.Table 2Author(s)Year of PublicationType of StudyNLocationKey FindingsUnilateral/BilateralRisk FactorAML/Other MDsType of TreatmentPrognosisLim et al.2018 (Turkey)Case report1Extra-conalMultifocal involvementUnilateralNTRAMLCTMedian remission 30 mCheng et al.2018 (China)Case report1Intra-conalNTRUnilateralTraumaAbsentCT + RTDisease-free at 24 m follow upWang et al.2018 (USA)Case report1Sphenoid wingMultifocal skeletal involvementUnilateralNTRAbsentCTNAGupta et al.2017 (India)Case report1Retro-conalNTRUnilateralNTRAMLCTRelapse at 12 m follow upSiraj et al.2017 (India)Case series1Extra-conalNTRUnilateralNTRAMLCT + RTDisease-free at 18 m follow upQian et al.2016 (USA)Case report1Extra-conalNTRUnilateralNTRAbsentCTNAMohanlal et al.2016 (South Africa)Case report1Extra-conal, peri-orbitalGlycophorin A positiveUnilateralNTRPELCTNAHuanh et al.2015 (Taiwan)Case report1Extra-ocular musclesNTRBilateralNTRAMLCTDisease-free at 12 m follow upKarmegaraj et al.2014 (India)Case report1Peri-orbitalFlu-like onsetBilateralNTRAMLCTDisease-free at follow upAggarwal et al.2014 (India)Original article23Either intra- or extra-conalNAUnilateralNA23 AMLCTMedian remission 36 mThakur et al.2013 (India)Case report2NA; NANTRUnilateral; UnilateralNTR2 AMLNA; NANA; NADinand et al.2013 (India)Case report1Extra-conal, intra-conalNTRUnilateralNTRAbsentCTDisease-free at 6 m follow upChaudhry et al.2012 (Saudi Arabia)Case report1Extra-conalNTRUnilateralNTRAMLCTDisease-free at 10 m follow upJohnston et al.2012 (USA)Original article23NA15/23 CNS involvementNANA19 AML; 4 AbsentCT + RTRemission at 12 m follow upIsik et al.2011 (Turkey)Case report2Retroconal; Intra-conal,NTRUnilateralNTR2 AbsentCT; CTBoth disease-free at follow upBaldwin et al.2010 (USA)Case report1Extra-conalNTRUnilateralNTRAMLCT + RTDisease-free at 20 m follow upAlkatan et al.2008 (Saudi Arabia)Case report1Extra-conalNTRUnilateralNTRAbsentNANAHmidi et al.2007 (Tunisia)Case report1Extra-conalNTRUnilateralNTRAMLCTDisease-free at 24 m follow upJanic et al.2007 (Serbia)Case report1NAKidney involvementBilateralNTRAbsentCTNAChoo et al.2006 (USA)Case report1Extra-conalNTRUnilateralNTRAMLNANABhat et al.2005 (India)Case report1Extra-conalNTRUnilateralTraumaAbsentS + CT + RTRelapse 3 m after treatmentPorto et al.2004 (Germany)Case series3Extra-conal; Extra- and intra-conal; Extra-conalPrevious neuroblastoma; NTR; NTRUnilateral; Unilateral; UnilateralNTR; NTR; NTR3 AMLCT; CT; CTDeceased few months from diagnosis; Remission; NASöker et al.2003 (turkey)Case report1Extra-conalNTRBilateralNTRAMLNANAShields et al.2003 (USA)Case report1Extra-conalNTRBilateralNTRAMLCTDisease-free at 3 m follow upSteinwexler et al.2002 (USA)Case report1Extra-conalNTRUnilateralNTRAMLCTDisease-free at 1 m follow upBönig et al.2002 (Germany)Case report1Extra- and retro-conalNTRUnilateralNTRAMLCT + RTDisease-free at 20 m follow upFisgin et al.2002 (Turkey)Case report1Extra- and intra-conalPVB19 infectionBilateralNTRAMLCTRemission at follow upHung et al.2002 (Taiwan)Case report1Extra- and intra-conalNTRBilateralNTRAMLCTDisease-free at 19 m follow upBisschop et al.2001 (NL)Original article35NANANANA35 AMLCTNAUyesugi et al.2000 (USA)Case report1Extra- and intra-conalNTRBilateralNTRAMLCT + RTDeceased 1 m from diagnosisLakhkar et al.2000 (India)Case report1Extra-conalNTRBilateralNTRNACTRemission at follow upFelice et al.1999 (Argentina)Original article5Either intra- or extra-conalNANANA5 AML1 S + CT;\
1 RT + CT;\
3 CT7 Remission at follow up; 1 Deceased within 1y from diagnosisPuri et al.1999 (UK)Case report1Extra-ocular musclesNTRUnilateralNTRAMLCTNASchwyzer et al.1999 (South Africa)Original article9All extra-conal and peri-orbitalNAEither unilateral or bilateralNA9 AMLCT8 Remission at follow up; 1 No RemissionLuckit et al.1998 (UK)Case report1Retro-conalNTRUnilateralNTRAMLCTDisease-free at 42 m follow upTanigawa et al.1998 (Japan)Case report1Extra-conalNTRUnilateralNTRAMLCTRemission at follow upStockl et al.1997 (Canada)Original article7NANTRUnilateralNTR7 AMLCTRemission at follow upGirardot et al.1996 (Morocco)Case report1Extra-conalNTRUnilateralNTRAMLCT + RTDisease-free at 36 m follow upHiçsönmez et al.1996 (Turkey)Case report1NANTRUnilateralNTRAMLCTDisease-free at 36 m follow upBulas et al.1995 (USA)Case report1Extra-conalNTRBilateralNTRAMLCTNo remission al follow upPui et al.1994 (USA)Original article31NANANANA30 AML;\
1 CML18 CT;\
9 CT + RT;\
3 S + CT;\
1 S + RT + CT16 Deceased 2.5--143.9 m from diagnosis; 15 Disease-freeCavdar et al.1993 (Turkey)Case report1Intra-conalNTRBilateralNTRAMLCTDeceased 7 m from diagnosisCavdar et al.1993 (Turkey)Original article10Either intra- or extra-conalNAEither unilateral or bilateralNA10 AMLCTNAKalmanti et al.1991 (Greece)Case report2Retroconal; Extra-conalNTRUnilateral; UnilateralNTR2 AMLCT; CTDisease-free at 8y follow up; Deceased 2y from diagnosisBanna et al.1991 (Saudi Arabia)Case series4Either intra- or extra-conalNTR2 Unilateral; 2 BilateralNTR4 AMLCT + RTNACavdar et al.1989 (Turkey)Original article33Either intra- or extra-conalNA17 Bilateral; 16 UnilateralNA21 AML; 12 AbsentCTAll deceased within 20 m from diagnosisDavis et al.1985 (USA)Case report1Extra-ocular musclesCNS involvementUnilateralNTRAMLCTRemission at follow upRajantie et al.1984 (Finland)Case report1Extra-conalNTRUnilateralNTRAMLS + CTDeceased 11 m from diagnosisCavdar et al.1978 (Turkey)Original article20NANA11 Unilateral; 9 BilateralNA20 AMLCTMedian remission 9 m[^2]

Since orbital MS has been generally thought to be an antecedent disease entity able to evolve into AML, treatment strategies have been mainly focused on inducing a remission to prevent evolution to AML: isolated MS left untreated, commonly evolves into AML within 1 year.[@bib25] Regarding therapeutic options, due to tumor rarity, no universal consensus on the best treatment planning has yet been reached and no unified protocol has been identified. Out of 6 patients with isolated orbital MS who initially received high-dose methylprednisolone treatment, followed by the Acute Myeloid Leukemia-Berlin Frankfurt Munster 2004 treatment protocol, 2 (33.3%) later developed AML; on the other hand, out of 12 patients with isolated MS who received only external beam radiotherapy, 11 (91.7%) developed AML during the follow-up period.[@bib26]

Lee et al. reported that 22.2% of patients with isolated MS who had undergone only local treatment (such as surgery and/or local radiotherapy) did not progress to AML, particularly with a complete remission durations of 1.8 months whose treatment was surgery alone and 83.9 months for those who received radiotherapy; at the same time these Authors also reported that, in contrast, 44.4% of patients who received systemic chemotherapy treatment had evolved to AML within a median time of 13.4 months.[@bib27] Tsimberidou et al. reported a review of 20 cases of non-leukemic MS in which the combined treatment with chemotherapy and radiotherapy resulted in better survival than chemotherapy alone.[@bib28] Therefore local treatment, such as surgery or radiotherapy, might play an important role in controlling primary disease and relieving symptoms, without significant toxicity and additional risk of evolution into AML.[@bib29]^,^[@bib30] Nevertheless, although the number of isolated orbital lesions is very limited and the treatment results reported in literature are still confusing, it seems that combining systemic and local treatment for patients with isolated orbital MS might be a more promising therapeutic strategy to achieve complete remission compared with any other treatment alone. In this light, after gross surgical resection the first patient received systemic chemotherapy with complete remission at one-year follow-up and the second patient received a systemic chemotherapy with complete remission at 6 months follow-up and disease free at four years follow up.

5. Conclusion {#sec5}
=============

MS generally occurs in patients with AML, but it can also occasionally precede myeloproliferative disorders within a matter of months in patients with no evidence of hematological disease at the time of bone marrow aspiration and biopsy at the initial diagnosis (isolated, primary or non-leukemic MS). Particularly in these patients, a prompt diagnosis of MS is essential to the most effective clinical management, because conventional AML-type chemotherapy and or allogeneic hematopoitic cell transplantation improves overall free survival. In this light it is important to recognize the few radiological features that can guide the radiologist in differentiating orbital MS from other pediatric orbital masses. Eventually the use of multi-planar and multi-parametric MRI, with particular reference to diffusion weighted and contrast-enhanced sequences, may be crucial to the purpose.
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[^1]: Legend: MS = Myeloid Sarcoma; MD = Myeloproliferative Disease; AML = Acute Myeloid Leukemia; CML = Chronic Myeloid Leukemia.

[^2]: Legend: N = Number of patients; AML = Acute Myelocytic Leukemia; MDs = Myelodysplastic Disease; NTR = Nothing To Report; CT = Chemotherapy; RT = Radiotherapy; S = Surgery NA = Not Available; PEL = Pure Erythroid Leukemia; CNS = Central Nervous System.
